Natera/$NTRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Natera
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Ticker
$NTRA
Sector
Primary listing
Employees
6,138
Headquarters
Website
Natera Metrics
BasicAdvanced
$28B
-
-$1.52
1.70
-
Price and volume
Market cap
$28B
Beta
1.7
52-week high
$256.36
52-week low
$125.38
Average daily volume
1.3M
Financial strength
Current ratio
3.393
Quick ratio
3.111
Long term debt to equity
6.918
Total debt to equity
11.609
Interest coverage (TTM)
-76.16%
Profitability
EBITDA (TTM)
-270.727
Gross margin (TTM)
64.75%
Net profit margin (TTM)
-9.03%
Operating margin (TTM)
-13.44%
Effective tax rate (TTM)
22.35%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-9.54%
Return on equity (TTM)
-14.32%
Valuation
Price to revenue (TTM)
11.761
Price to book
16.18
Price to tangible book (TTM)
23.14
Price to free cash flow (TTM)
356.348
Free cash flow yield (TTM)
0.28%
Free cash flow per share (TTM)
0.557
Growth
Revenue change (TTM)
35.90%
Earnings per share change (TTM)
-0.28%
3-year revenue growth (CAGR)
41.14%
10-year revenue growth (CAGR)
28.33%
3-year earnings per share growth (CAGR)
-35.09%
10-year earnings per share growth (CAGR)
-5.50%
What the Analysts think about Natera
Analyst ratings (Buy, Hold, Sell) for Natera stock.
Natera Financial Performance
Revenues and expenses
Natera Earnings Performance
Company profitability
Natera News
AllArticlesVideos
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
Business Wire·3 days ago
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation
Business Wire·3 weeks ago
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Natera stock?
Natera (NTRA) has a market cap of $28B as of March 19, 2026.
What is the P/E ratio for Natera stock?
The price to earnings (P/E) ratio for Natera (NTRA) stock is 0 as of March 19, 2026.
Does Natera stock pay dividends?
No, Natera (NTRA) stock does not pay dividends to its shareholders as of March 19, 2026.
When is the next Natera dividend payment date?
Natera (NTRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Natera?
Natera (NTRA) has a beta rating of 1.7. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.